Cell
Volume 182, Issue 3, 6 August 2020, Pages 713-721.e9
Journal home page for Cell

Article
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

https://doi.org/10.1016/j.cell.2020.06.008Get rights and content
Under an Elsevier user license
open archive

Highlights

  • An inactivated SARS-CoV-2 vaccine candidate, BBIBP-CorV, is developed

  • BBIBP-CorV induces high levels of neutralizing antibodies titers in animal models

  • Two-dose immunization with 2 μg/dose BBIBP-CorV efficiently protects rhesus macaques

  • BBIBP-CorV is efficiently produced, genetically stable, and seems to be safe in animals

Summary

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.

Keywords

SARS-CoV-2
inactivated vaccine
BBIBP-CorV

Cited by (0)

6

These authors contributed equally

7

Lead Contact